ALOX15 and coronary atherosclerosis: Notably, in vivo levels of LXA4 are decreased in patients with peripheral and coronary atherosclerosis,118 and the overexpression of 12-LOX and 15-LOX in macrophages of atherosclerotic ApoE-deficient mice increase LXA4 production and hamper atherosclerotic lesion development.